Hillhouse and Japan’s Mitsui & Co have emerged as final bidders vying for Singapore-headquartered traditional Chinese medicine chain Eu Yan Sang International, in a deal that could fetch over $700 million, two people with knowledge of the matter said.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com